Scarica l'app Stockscreener
8.855
3.59%
-0.335
Precedente Chiudi:
$9.19
Aprire:
$9.14
Volume 24 ore:
129.12K
Relative Volume:
0.11
Capitalizzazione di mercato:
$481.49M
Reddito:
$2.85M
Utile/perdita netta:
$-143.44M
Rapporto P/E:
-3.3249
EPS:
-2.6632
Flusso di cassa netto:
$-133.44M
1 W Prestazione:
-3.49%
1M Prestazione:
-8.66%
6M Prestazione:
-61.41%
1 anno Prestazione:
+3.26%
Intervallo 1D:
$8.69
$9.14
Intervallo di 1 settimana:
$8.69
$9.57
Portata 52W:
$7.25
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Nome
Upstream Bio Inc
Settore
Industria
Telefono
781-208-2466
Indirizzo
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
8.8477 | 500.12M | 2.85M | -143.44M | -133.44M | -2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
711.31 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.00 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-11-18 | Iniziato | Evercore ISI | Outperform |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Iniziato | William Blair | Outperform |
Mostra tutto
Upstream Bio Inc Borsa (UPB) Ultime notizie
Jennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPB - MarketBeat
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
UPB Forecast, Price Target & Analyst Ratings | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Segment Overview and Major Growth Areas in the Upstream Bioprocessing Market - openPR.com
Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Upstream Bio (UPB) Stock Bonus Issue (Bearish Sentiment) 2026-04-20Bullish Pattern - Newser
Upstream Bio (UPB) Stock Ask Wall (Trend Weakens) 2026-04-18Upside Potential - Cổng thông tin điện tử tỉnh Lào Cai
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Sahm
Upstream Bio to present verekitug data at medical conference By Investing.com - Investing.com Australia
Upstream Bio to present verekitug data at medical conference - Investing.com
Can Upstream Bio (UPB) Stock Beat Estimates | Price at $10.24, Down 2.38%AI Stock Signals - Newser
Bull Bear: Is Upstream Bio Inc a cyclical or defensive stock2026 Intraday Action & Low Drawdown Trading Strategies - baoquankhu1.vn
UPB Options Volatility — NASDAQ:UPB - TradingView — Track All Markets
UPB Options Chain — NASDAQ:UPB - TradingView
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward - TipRanks
Earnings Update: Is Upstream Bio Inc still a buy after recent gains2026 Rallies & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and Pfizer (PFE) - The Globe and Mail
Truist cuts Upstream Bio stock price target on trial timeline By Investing.com - Investing.com Canada
Market Recap: Is Upstream Bio Inc forming a bullish divergence2026 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Piper Sandler Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Upstream Bio, Inc. (UPB) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Retail Surge: Does Upstream Bio Inc have a sustainable dividendTrade Signal Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
UpStream Bio | 10-K: FY2025 Annual Report - Moomoo
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen - MarketBeat
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors - TipRanks
Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line - MarketBeat
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $15 to $42 - moomoo.com
Upstream Bio Inc Azioni (UPB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Upstream Bio Inc Azioni (UPB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
5.78%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):